SCHEMBL12376738

SCHEMBL12376738

CC(=O)c1ccc(S(=O)(=O)NC(C)C)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A3 P43003 1/20 0.60
SLC1A2 P43004 1/20 0.60
SLC1A1 P43005 1/20 0.60
CA1 P00915 1/20 0.59
CA2 P00918 1/20 0.59
CA12 O43570 1/20 0.56
CA9 Q16790 1/20 0.56
MEN1 O00255 4/20 0.55
KMT2A Q03164 4/20 0.55
NPSR1 Q6W5P4 1/20 0.55
LMNA P02545 4/20 0.55
MAPT P10636 4/20 0.54
HPGD P15428 3/20 0.54
ALDH1A1 P00352 5/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
FFAR4 Q5NUL3 1/20 0.53
CYP19A1 P11511 1/20 0.50
THRB P10828 1/20 0.50
TSHR P16473 1/20 0.50
BLM P54132 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2594879 0.85 NPSR1 (0.59) CA1CA2CA12CA9MEN1
SCHEMBL29954313 0.84 ADAMTS4 (0.67) SLC1A3SLC1A2SLC1A1CA1CA2
SCHEMBL29957122 0.84 ADAMTS4 (0.67) SLC1A3SLC1A2SLC1A1CA1CA2
SCHEMBL5453601 0.84 NPSR1 (0.54) SLC1A3SLC1A2SLC1A1CA1CA2
SCHEMBL13545225 0.81 NPSR1 (0.55) MEN1KMT2ANPSR1LMNAMAPT
SCHEMBL13543279 0.81 NPSR1 (0.51) MEN1KMT2ANPSR1LMNAMAPT
SCHEMBL12376737 0.80 HTR2B (0.62) CA1CA2KMT2ALMNAMAPT
SCHEMBL27214045 0.80 NPSR1 (0.54) MEN1KMT2ANPSR1LMNAMAPT
SCHEMBL7908701 0.79 POLB (0.68) CA1CA2CA12CA9MEN1
SCHEMBL3747089 0.79 ADAMTS4 (0.58) CA1CA2CA12CA9MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8003662-B2 Heterobicyclic thiophene compounds and methods of use ARRAY BIOPHARMA, INC. (US) 2011-08-23 US disclosed
US-20100256356-A1 HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE ARRAY BIOPHARMA INC. (US) 2010-10-07 US disclosed
US-7723330-B2 Heterobicyclic pyrazole compounds and methods of use ARRAY BIOPHARMA INC. (US) 2010-05-25 US disclosed
US-20070238726-A1 Heterobicyclic pyrazole compounds and methods of use GENENTECH, INC. 2007-10-11 US disclosed
US-20070197537-A1 Heterobicyclic thiophene compounds and methods of use ARRAY BIOPHARMA, INC. 2007-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197537-A1 Heterobicyclic thiophene compounds and methods of use ERBB2, LCK, SRC SLC1A3 1823/4885SLC1A2 1054/4885SLC1A1 1184/4885
US-20100256356-A1 HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE ROR1, CYP11B1, CYP11B2 SLC1A3 1405/4885SLC1A2 1219/4885SLC1A1 1215/4885
US-20070238726-A1 Heterobicyclic pyrazole compounds and methods of use ROR1, CYP11B1, CYP11B2 SLC1A3 1405/4885SLC1A2 1219/4885SLC1A1 1215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.